A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

The clinical utility of subcutaneous hirudins is discussed. The term "hirudins" refers to a class of antithrombotic agents structurally derived from the medicinal leech salivary protein hirudin.

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and ...

KORU Medical Systems is poised for growth with solid revenue increases and multiple growth drivers. Find out why KRMD stock ...

Celltrion plans to commercialize 22 biosimilars by 2030, expanding its global presence with robust sales growth driven by ...

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

We have seen a number of dynamic changes in MDS over the last few years, and integrating them into our treatment paradigm will impact our approach, and perhaps offer a glimpse into the future." ...

Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells – – Subcutaneous AK006 was well-tolerated with a favorable safety ...

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in obesity and knee osteoarthritis.

CBL-514's last Phase 2b study has been completed; Both CBL-514 Phase 2b studies used efficacy assessment tools, AFRS and ...